StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)

Close on Nov 17, 2026Market cap $253.10MP/E –Yield –

Enanta Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Enanta Pharmaceuticals's pe ratio was 545.4× on Oct 30, 2020, against 19.8× a year earlier. Over the last 5 years it ranged from 6.3× to 652.4×, with a median of 22.7×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Oct 30, 2020545.4×+517.4
2019Dec 31, 201928.0×+7.6
2018Dec 31, 201820.4×−44.1
2017Dec 29, 201764.5×+34.8
2016Dec 30, 201629.6×+21.6
2015Dec 31, 20158.1×−20.2
2014Dec 31, 201428.3×−22.6
2013Dec 31, 201350.8×–

More Enanta Pharmaceuticals figures

See a number that looks wrong?